K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · BIOGEN INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | BIIB | BIOGEN INC. | DLA PIPER LLP (US) | $60K | Issues related to tax reform. Trade-related public policy around tariffs and intellectual property. Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D. Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical pat |
| 2026-04-20 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2026-04-20 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program. |
| 2026-04-20 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to the budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the budget and appropriations process |
| 2026-03-09 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2026-01-20 | BIIB | BIOGEN INC. | DLA PIPER LLP (US) | $60K | Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D. Issues related to tax reform. Trade-related public policy around tariffs and intellectual property. Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical pat |
| 2026-01-20 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. 340B Program. PPRV (Pediatric Priority Review Voucher) program. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. 340B Program. |
| 2026-01-20 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to the FY2026 budget and appropriations process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to the FY2026 budget and appropriations process |
| 2026-01-09 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2025-10-20 | BIIB | BIOGEN INC. | DLA PIPER LLP (US) | $60K | Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D. Issues related to tax reform. Trade-related public policy around tariffs and intellectual property. Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. Intellectual property protections and enforcement. Biopharmaceutical pat |
| 2025-10-20 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2025-10-20 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. |
| 2025-10-20 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Monitoring issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Monitor issues related to the FY2026 budget process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Monitor issues related to the FY2026 budget process Issues related to tax reform and the FY2026 budget process |
| 2025-09-25 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2025-07-21 | BIIB | BIOGEN INC. | DLA PIPER LLP (US) | $60K | Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. Intellectual property protections and enforcement. Biopharmaceutical patent policy. Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing supply chain. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Drug pricing. Supply chain issues and gene therapy. Policies related to value based arrangements and implementation of Inflation Reduction Act of 2022. Issues related to rare disease and treatment. Pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Med |
| 2025-07-21 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Monitoring issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Monitor issues related to the FY2025 budget reconciliation process Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Monitor issues related to the FY2025 budget reconciliation process Issues related to tax reform and the FY2025 budget reconciliation process |
| 2025-07-19 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. |
| 2025-07-18 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2025-07-01 | BIIB | BIOGEN INC. | DLA PIPER LLP (US) | $0 | Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement. Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement. |
| 2025-04-21 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. |
| 2025-04-21 | BIIB | BIOGEN INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $50K | Issues related to Medicare Part B and Part D Issues related to the pharmaceutical industry |
| 2025-04-21 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Monitoring issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to rare diseases and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to tax reform |
| 2025-01-21 | BIIB | BIOGEN INC. | FEDERAL STREET STRATEGIES, LLC | $50K | Monitoring issues related to Alzheimer's Disease and treatment. Amyotrophic lateral sclerosis (ALS), Lou Gehrigs Disease and treatment. Issues related to Alzheimer's Disease and treatment. Issues related to Mental Health treatment. Issues related to maternal health. Issues related to rare diseases. |
| 2025-01-21 | BIIB | BIOGEN INC. | TODD STRATEGY GROUP | $50K | Alzheimer's Disease. Medicare Reimbursement for Prescription Drugs. Screening and Diagnosis, PET scan coverage and reimbursement and dementia care. Drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements. Implementation of Inflation Reduction Act of 2022. Issues related to maternal health. |